CTI BIOPHARMA CORP — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/936c551b-3b69-466d-a1b8-48e96efcebe5/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-79.8M | 2022-01-01 – 2022-12-31 | evidence 0000891293-23-000011 |
| FY 2021 | $-95.3M | 2021-01-01 – 2021-12-31 | evidence 0000891293-22-000010 |
| FY 2020 | $-47.8M | 2020-01-01 – 2020-12-31 | evidence 0000891293-21-000008 |
| FY 2019 | $-40.7M | 2019-01-01 – 2019-12-31 | evidence 0000891293-20-000012 |
| FY 2018 | $-32.9M | 2018-01-01 – 2018-12-31 | evidence 0000891293-19-000021 |
| FY 2017 | $-39.5M | 2017-01-01 – 2017-12-31 | evidence 0000891293-18-000043 |
| FY 2016 | $-49.2M | 2016-01-01 – 2016-12-31 | evidence 0000891293-17-000030 |
| FY 2015 | $-116.7M | 2015-01-01 – 2015-12-31 | evidence 0000891293-16-000105 |
| FY 2014 | $-86.2M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001582 |
| FY 2013 | $-41.5M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-082598 |
| FY 2012 | $-101.5M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-084836 |
| FY 2011 | $-62.2M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-103788 |
| FY 2010 | $-78.4M | 2010-01-01 – 2010-12-31 | evidence 0001193125-13-084836 |
| FY 2009 | $-81.6M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-103788 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).